Newswire (Published: Thursday, November 18, 2021, Received: Thursday, November 18, 2021, 5:47:33 PM CST)

Word Count: 529

2021 NOV 18 (NewsRx) -- By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News -- New research on Machine Learning is the subject of a report. According to news reporting out of Brest, France, by NewsRx editors, research stated, “Low-dose-rate brachytherapy is a key treatment for low-risk or favorable intermediate-risk prostate cancer. The number of radioactive seeds inserted during the procedure depends on prostate volume, and is not easy to predict without pre-planning.”

Our news journalists obtained a quote from the research from the University of Brest, “Consequently, a large number of unused seeds may be left after treatment. The objective of the present study was to predict the exact number of seeds for future patients using machine learning and a database of 409 treatments. Database consisted of 18 dosimetric and efficiency parameters for each of 409 cases. Nine predictive algorithms based on machine-learning were compared in this database, which was divided into training group (80%) and test group (20%). Ten-fold cross-validation was applied to obtain robust statistics. The best algorithm was then used to build an abacus able to predict number of implanted seeds from expected prostate volume only. As an evaluation, the abacus was also applied on an independent series of 38 consecutive patients. The best coefficients of determination were given by support vector regression, with values attaining 0.928, 0.948, and 0.968 for training set, test set, and whole set, respectively. In terms of predicted seeds in test group, mean square error, median absolute error, mean absolute error, and maximum error were 2.55, 0.92, 1.21, and 7.29, respectively. The use of obtained abacus in 38 additional patients resulted in saving of 493 seeds (393 vs. 886 remaining seeds). Machine-learning-based abacus proposed in this study aims at estimating the necessary number of seeds for future patients according to past experience.”

According to the news editors, the research concluded: “This new abacus, based on 409 treatments and successfully tested in 38 new patients, is a good alternative to non-specific recommendations.”

For more information on this research see: A machine-learning approach based on 409 treatments to predict optimal number of iodine-125 seeds in low-dose-rate prostate brachytherapy. Journal of Contemporary Brachytherapy, 2021;13(5):541-548. Journal of Contemporary Brachytherapy can be contacted at: Termedia Publishing House Ltd, Kleeberga St 2, Poznan, 61-615, Poland.

Our news journalists report that additional information may be obtained by contacting Ulrike Schick, LaTIM, French National Institute of Health and Medical Research (INSERM), UMR 1101, University of Brest, Brest, France. Additional authors for this research include Nicolas Boussion, Gurvan Dissaux, Luc Ollivier, Gaelle Goasduff, Olivier Pradier, Antoine Valeri and Dimitris Visvikis.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.5114/jcb.2021.109789. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Journal of Contemporary Brachytherapy is: Termedia Publishing House Ltd, Kleeberga St 2, Poznan, 61-615, Poland.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

Inserm

Industries

Information and Media
      Publishing

Places

Eastern Europe
Western Europe
France
Poland
Europe

Subjects

Science and Technology
      Scientific Research
      Technology
            Artificial Intelligence
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer